Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

European Journal of Cancer

Volumn 36, Issue 18, 2000, Pages 2344-2352

  Gonzalez Larriba J L ^a   Serrano, S ^b   Alvarez Mon, M ^c   Camacho, F ^d   Casado, M A ^e   Diaz Perez J L ^f   Diaz Rubio E ^a   Fosbrook, L ^e   Guillem, V ^g   Lopez Lopez J J ^h   Moreno Nogueira, J A ⁱ   Toribio, J ^j  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e Schering Plough   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j HOSPITAL GENERAL DE GALICIA   (Spain)

more..

Author keywords

Cost effectiveness; Interferon; Melanoma

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SKIN NEOPLASMS;

EID: 0033695538     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00304-X     Document Type: Article

References (36)

1. Cancer statistics, 1997
2. Finally, a successful adjuvant therapy for high-risk melanoma
3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
4. An estimate of the annual direct cost of treating cutaneous melanoma
5. Guidelines for authors and peer reviewers of economic submissions to the BMJ
6. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684
7. Prognostic factors in 1,521 melanoma patients with distant metastases
8. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
9. The annual risk of melanoma progression. Implications for the concept of cure
10. Late recurrence of malignant melanoma. Analysis of 168 patients
11. Coste-efectividad de la hepatitis cronica C con interferon alfa
12. A comparative cost analysis of terminal cancer care in home hospice patients and controls
13. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
14. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation
15. Economic analysis of benefit from interferon-alpha 2b in high-risk melanoma: Trade-offs between completeness, simplicity and clarity
16. Discounting and health benefits
17. Cost-effectiveness analysis
18. Years of potential life lost: Another indicator of the impact of cutaneous malignant melanoma on society
19. Screening for melanoma by primary health care physicians: A cost-effectiveness analysis
20. Adjuvant therapy for cutaneous malignant melanoma
21. Adjuvant therapy of melanoma: Interferon and beyond
22. Adjuvant therapy for melanoma
23. Results of adjuvant interferon study in WHO melanoma programme
24. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
25. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
26. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
27. Issues in the cross-national assessment of health technology
28. El tratamiento sustitutivo de la insuficiencia renal cronica en Espana
29. Impacto economico de la incorporacion de nuevos avances biotecnologicos en el tratamiento de la insuficiencia renal cronica en Espana (1992)
30. Coste y calidad en el tratamiento de la insuficiencia renal terminal
31. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations